For decades, big pharma has operated on a familiar social contract: Discover important medicines, navigate regulation, and deliver returns to shareholders, and society will broadly accept your business model. That contract is fraying and the reality has become more complex. Public approval, policy scrutiny, and investor pressure increasingly reflect a different reality: What society values, talks about, and organizes around is now shaping revenue and profit almost as much as pipelines and patents and will continue to in the future.^[1][2][3][4]

Over the coming decade, five primary societal narratives will define big pharma’s “social balance sheet”. Executives who treat them as noise or as a branding problem will see rising friction across the value chain. Those who treat them as design constraints for strategy, operating models, and partnerships can unlock new growth, pricing resilience, and trust.^{[3][4][5][6][1]}

The challenge is not to chase every trend. It is to maintain a clear focus on good science and genuine patient centricity while deliberately deciding where and how societal narratives should guide business decisions from portfolio choices to launch messaging and alliances.^[2][5][7]

1. Longevity and the rise of “better years”

The first narrative is the longevity economy. Globally, populations are aging fast, and the proportion of people over 60 and 80 is set to rise sharply over the next few decades. Analysts now frame longevity not just as a looming cost driver but as a growth engine for economies and industries that design for older adults’ needs and capabilities.^[4][5][8][9]

Importantly, expectations are shifting from “more years” to “better years”. Older adults and their families increasingly value function, independence, cognitive health, and manageable caregiving demands as much as they value survival. Our own perspective (here) on aging and the longevity economy highlights how these expectations intersect with caregiver shortages, the rise of home‑based care, and growing digital literacy among older adults. This does not just change clinical priorities; it changes the questions society asks of big pharma: “Does this therapy actually help my parent live better, or just live longer in a fragmented system?”^{[5][8][10][4]}

For R&D and portfolio strategy, this narrative should guide, not dictate, decisions. Science still sets feasibility and safety boundaries. However, when choosing between adjacent indications or target product profiles, longevity expectations can influence which programs move forward. Therapies that meaningfully improve function, reduce caregiver burden, or support aging in place will likely find stronger pull from health systems, payers, and families. In evidence planning, this means expanding endpoints beyond traditional hard outcomes to include measures of mobility, cognition, treatment burden, and caregiver impact, along with digital measures that capture everyday function.^{[8][10][11][2][3][5]}

In commercial and market access, longevity as “better years” should inform how products are positioned, how services are designed, and which partners you select. The question is not “How do we wrap longevity language around our existing brands,” but “Which combinations of therapy, digital support, and services measurably move the needle on the lived experience of aging?” Here, social narratives are most useful as a directional compass, not as a substitute for rigorous health economic modeling.^{[10][12][1][2][3][5]}

2. Whole‑person, holistic patient experience

The second narrative is the consumerization of healthcare and the demand for whole‑person care. Patients and caregivers increasingly expect experiences that feel integrated, respectful, and tailored to their realities, not journeys defined by organizational silos. Trends in healthcare consumer experience show rising expectations for omnichannel access, personalized support, and frictionless transitions across providers and digital touchpoints.^{[11][12][13][14]}

For life science companies, this means launches are no longer just about getting the label and the sales force right. Many category‑defining products now operate as service businesses anchored on a molecule: they depend on digital tools, hubs, adherence programs, and human support that make the therapy usable in complex, real‑world contexts. Health systems, payers, and advocacy groups expect manufacturers to contribute to solving adherence and care coordination challenges, not simply promote products.^{[7][12][15][3]}

Here, the risk is over‑rotating to experience language without changing underlying design. Patient centricity, especially in the longevity era, is not about better portals or slogans; it is about designing around burden of treatment, multi‑morbidity, cognitive load, and the distributed care ecosystem of family caregivers, home health, and community services. Good science and rigorous evidence remain non‑negotiable. The role of societal narratives is to broaden the definition of “value” beyond narrow clinical endpoints and to surface overlooked pain points that science can address.^{[12][13][14][8][10][11]}

Across the value chain, this shows up in several ways:

Social narratives should inform which friction points receive investment and how solutions are framed, but not override clinical judgment on what is safe and effective. When the narrative pulls in directions that conflict with evidence, companies have a responsibility to communicate clearly, correct misinformation, and, where appropriate, design better studies that address legitimate concerns.^[16][8][11]

3. “Clean,” transparent, and values‑aligned health

The third narrative is the rise of “clean” and values‑aligned health choices. Consumers increasingly focus on organic products, minimal processing, environmental footprint, and alignment with personal ethics, and these expectations spill into how they view pharmaceuticals, devices, and digital health. Even when the evidence behind some claims is uneven, these narratives shape trust, adherence, and willingness to initiate or persist with therapies.^{[6][4][12][16]}

For life science companies, dismissing this as fringe is risky. Conversations about long‑term safety, cumulative exposure, “toxic” ingredients, and environmental impact influence both everyday choices and organized activism. They also increasingly show up in procurement criteria, investor conversations, and regulatory discussions around environmental and health impacts across the lifecycle of products.^{[17][1][4][6]}

Balancing this narrative with good science requires discipline. On the R&D side, companies should not pivot to “natural” solutions purely because they are fashionable, but where mechanistic science supports it and where patient preferences genuinely support adherence and outcomes. What societal narratives can legitimately influence is the prioritization of programs that offer similar or better efficacy with improved safety, tolerability, or environmental profiles, and the design of formulations or delivery systems that reduce burden and perceived toxicity.^{[18][1][3][8]}

In evidence and communication, values‑aligned health pushes companies toward greater transparency: clearer explanation of benefit–risk trade‑offs, more accessible information about long‑term safety data, and honest discussion of uncertainties. It also opens space for partnership with adjacent players in nutrition, wellness, or digital behavior change, where the combined offer feels more aligned with how people want to manage their health. This is not about endorsing every trend; it is about connecting rigorous science with everyday choices.^{[6][11][12][16]}

Marketing and partnership messaging should be guided by a principle of “evidence‑first, values‑aware.” Social listening can help identify fears, misconceptions, and unmet needs, but the response should be grounded in data and ethics, not tailored to confirm every preference.^{[11][12][13][16]}

4. Climate, sustainability, and planetary health

The fourth narrative is climate and sustainability. Expectations are rising that all sectors, including life sciences, contribute meaningfully to climate goals and environmental stewardship. Environmental, social, and governance considerations now intersect with pricing, market access, and supply chain resilience. Analysts highlight that environmental performance, including emissions and waste, is increasingly relevant for investors, business partners, and health systems.^{[1][4][17][6]}

For big pharma, climate and sustainability narratives influence revenue and profit through multiple channels. Manufacturing and supply chains face climate‑related disruptions, regulatory changes, and potential carbon‑related pricing. Health systems and payers may increasingly incorporate environmental criteria in tenders and contracts, especially in markets where public procurement is sensitive to sustainability metrics. Reputationally, being perceived as lagging on climate commitments can affect brand trust and talent attraction, particularly among younger workforces and patient advocates.^{[19][20][2][4][1][6]}

Good science in this context is about understanding the full lifecycle impact of therapies and technologies, and investing in innovations that reduce waste, energy use, and environmental harm without compromising quality or safety. Societal narratives should guide questions like:^[8][18]

At the marketing and partnership level, climate narratives should inform, but not dominate, positioning. Overstating environmental benefits without robust data risks greenwashing and backlash. Instead, companies can integrate credible sustainability metrics into value propositions and partnership discussions, particularly where they align with health system objectives and policy priorities.^{[2][17][1][6]}

5. Data, AI ethics, and “human‑in‑the‑loop” trust

The fifth narrative centers on data and AI ethics. AI has moved from experimentation to embedded infrastructure across the value chain: in drug discovery, clinical trial design, pharmacovigilance, forecasting, and patient support. Regulators, professional societies, and policy groups are signaling tougher requirements around safety, bias, explainability, and human oversight.^{[9][21][3][7][16][1]}

Public concern is not abstract. High‑profile missteps in AI‑enabled care, whether clinical decision support gone wrong or opaque patient‑facing tools, quickly become narratives about trust, fairness, and human dignity. Our piece (here) on human‑in‑the‑loop AI emphasizes that AI is most effective when it augments, rather than replaces, clinicians and other experts, with clear accountability for decisions.^[7][9][16]

Balancing this narrative with scientific and operational goals requires robust governance. At the research and development stage, AI should be used to accelerate insights and generate hypotheses, with human experts critically assessing outputs and ensuring that datasets and models reflect diverse populations. At the clinical and post‑marketing stages, AI‑enabled tools for patient support or safety monitoring must have clear escalation paths, human review of alerts, and transparent communication to patients about how their data is used.^{[21][16][7][8]}

When partnering with technology companies, including AI providers such as Anthropic or others, pharma executives must treat AI ethics as a core due‑diligence topic, not a technical afterthought. This includes governance frameworks for data sharing, model validation, bias monitoring, and accountability when things go wrong. Social narratives here should guide questions like:^[16][7]

In marketing and communications, companies should neither over‑promise AI capabilities nor downplay risks. Transparent, measured language about what AI does and does not do can build trust, especially when paired with credible governance commitments.^[7][16]

Maintaining a focus on good science and patient centricity

Across all five narratives, the risk is either over‑reacting to social pressure or ignoring it. The path forward is to treat societal values as a strategic lens, not as a replacement for scientific rigor and patient‑centric ethics.^[3][1][2][5]

Good science provides the foundation: mechanisms, safety, efficacy, and robust evidence. Patient centricity ensures that science is directed toward meaningful outcomes for people, not just statistically significant endpoints. Societal narratives add a third dimension: they highlight where people’s lived experiences, fears, and aspirations point to gaps in current offerings or blind spots in how value is defined.^{[4][12][13][5][8][10][11]}

In practice, this means:

The guiding question is not “How do we give people what they say they want?” but “How do we align robust science and genuine patient benefit with what society values, in ways that are honest about trade‑offs?”^[2][5]

A simple lens for leaders

To operationalize this, senior leaders can use a three‑question lens when making major decisions at any point in the value chain:^[3][1]

Societal narratives are not a passing trend. They are the stories through which people make sense of aging, health, technology, and trust. By treating those stories as structured input to strategy, rather than noise or pure PR, life science leaders can maintain a clear focus on good science and patient centricity while deliberately shaping how their business evolves.^{[14][9][4][2][5][1][3]}

The question for every executive team is simple: If you had to show your board how your 2030 strategy aligns with these five narratives, where could you confidently point to evidence, and where would there be gaps?^[1][3]

References